Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Krishna Vaddi Acquires 10,000 Shares

Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Krishna Vaddi bought 10,000 shares of Prelude Therapeutics stock in a transaction that occurred on Monday, December 30th. The shares were acquired at an average cost of $1.20 per share, with a total value of $12,000.00. Following the acquisition, the chief executive officer now owns 137,553 shares of the company’s stock, valued at $165,063.60. The trade was a 7.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Krishna Vaddi also recently made the following trade(s):

• On Wednesday, December 18th, Krishna Vaddi bought 100,000 shares of Prelude Therapeutics stock. The shares were acquired at an average cost of $0.93 per share, with a total value of $93,000.00.

Prelude Therapeutics Stock Performance

PRLD stock opened at $1.39 on Friday. The firm has a market cap of $76.50 million, a PE ratio of -0.78 and a beta of 1.49. The firm’s fifty day moving average is $1.11 and its 200 day moving average is $2.99. Prelude Therapeutics Incorporated has a one year low of $0.80 and a one year high of $6.80.

Prelude Therapeutics (NASDAQ:PRLD) last announced its earnings results on Wednesday, November 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.05. The company had revenue of $3.00 million during the quarter. Research analysts predict that Prelude Therapeutics Incorporated will post -1.81 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Prelude Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of PRLD. Barclays PLC boosted its position in Prelude Therapeutics by 86.0% during the third quarter. Barclays PLC now owns 27,165 shares of the company’s stock worth $57,000 after acquiring an additional 12,564 shares during the last quarter. XTX Topco Ltd acquired a new position in Prelude Therapeutics during the third quarter worth about $100,000. Dimensional Fund Advisors LP boosted its position in Prelude Therapeutics by 103.2% during the second quarter. Dimensional Fund Advisors LP now owns 29,074 shares of the company’s stock worth $111,000 after acquiring an additional 14,769 shares during the last quarter. Exchange Traded Concepts LLC boosted its position in Prelude Therapeutics by 32.2% during the third quarter. Exchange Traded Concepts LLC now owns 64,409 shares of the company’s stock worth $133,000 after acquiring an additional 15,682 shares during the last quarter. Finally, Walleye Capital LLC raised its stake in Prelude Therapeutics by 446.2% during the third quarter. Walleye Capital LLC now owns 83,175 shares of the company’s stock worth $172,000 after purchasing an additional 67,946 shares during the period. 79.72% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. JMP Securities reissued a “market outperform” rating and set a $4.00 target price (down previously from $7.00) on shares of Prelude Therapeutics in a report on Wednesday, December 11th. HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of Prelude Therapeutics in a research report on Friday, November 8th.

Prelude Therapeutics Company Profile

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.